Author:
Kim Sung-Ho,Lee Sung-Hack,Yim Hyeon-Joo
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,Drug Discovery,Molecular Medicine
Reference12 articles.
1. Cefalu, W.T., and S. Urquhart. 2007. Clinical management strategies for type 2 diabetes. Journal of the American Academy of Physician Assistants Suppl: 9–14.
2. Drucker, D.J. 2007. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30: 1335–1343.
3. Hwang, D.M., S.H. Kim, M.K. Yoon, O.H. Kwon, K.D. Koo, C.H. Min, S.H. Lee, J.I. Lee, C.S. Lee, H.J. Yim. 2008. LC15-0444 is a novel, potent, selective, and orally active dipeptidyl peptidase IV inhibitor. Poster presented at the annual meeting of American Diabetes Association. San Francisco: CA.
4. Kim, S.E., S. Yi, K.H. Shin, T.E. Kim, M.J. Kim, Y.H. Kim, S.H. Yoon, J.Y. Cho, S.G. Shin, I.J. Jang, and K.S. Yu. 2012. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 50: 17–23.
5. Lankas, G.R., B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.C. Chan, S. Edmondson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, S.K.A. Lyon, H.O. Ok, R.A. Patel, A.N. Petrov, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J.K. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry. 2005. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54: 2988–2994.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献